ANGN Angion Biomedica Corp.

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitor for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was founded in 1998 and is headquartered in Uniondale, New York.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/05/2021
Outstanding shares:  29,956,483
Average volume:  216,380
Market cap:   $107,843,339
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03476J107
ISIN:        US03476J1079
Sedol:      BMD8P43
Valuation   (See tab for details)
PE ratio:   -1.02
PB ratio:   1.55
PS ratio:   38.11
Return on equity:   -152.43%
Net income %:   -3,474.84%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy